Novilla Pharmaceuticals Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$18M
- Investors
-
7
Novilla Pharmaceuticals General Information
Description
Developer of pain therapeutics designed for opioid treatment. The company's platform utilizes patented drug delivery mechanisms for deep penetration of established therapies that can be delivered to a site of action while avoiding exposure to the rest of the body, enabling patients to receive effective pain management with minimal systemic exposure and reduced side effects.
Contact Information
Website
www.novilla.comCorporate Office
- 1520 Belle View Boulevard Unit
- Suite 5266
- Arlington, VA 22307
- United States
Corporate Office
- 1520 Belle View Boulevard Unit
- Suite 5266
- Arlington, VA 22307
- United States
Novilla Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A2) | 30-Sep-2026 | $18M | Completed | Clinical Trials - Phase 1 | ||
| 3. Seed Round | 01-Nov-2021 | Completed | Startup | |||
| 2. Accelerator/Incubator | $3M | Completed | Startup | |||
| 1. Seed Round | 01-Jan-2019 | $3M | $3M | Completed | Startup |
Novilla Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | ||||||||
| Seed 2 | 1,638,033 | $0.000100 | 8% | $2.04 | $2.04 | 1x | $2.04 | 6.98% |
| Seed 1 | 2,608,121 | $0.000100 | 8% | $3.04 | $3.04 | 1x | $3.04 | 11.12% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Novilla Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Novilla Pharmaceuticals Patents
Novilla Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026161636-A1 | Topical l-arginine compositions | Pending | 24-Jan-2025 | ||
| US-20260207555-A1 | Topical ketorolac compositions | Pending | 20-Nov-2024 | ||
| WO-2026112195-A1 | Topical ketorolac compositions | Pending | 20-Nov-2024 | ||
| US-12440438-B2 | Method of remotely controlling pain | Active | 22-Jul-2019 | ||
| US-20210022993-A1 | Method of remotely controlling pain | Active | 22-Jul-2019 | A61K45/06 |
Novilla Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Novilla Pharmaceuticals Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| MALIAM | Corporation | Minority | ||
| 3rdEyeBio | Accelerator/Incubator | Minority | ||
| Beyond The Game Network | Venture Capital | Minority | ||
| Ringbolt Capital | Venture Capital | Minority | ||
| Blindspot Ventures | Venture Capital | Minority |
Novilla Pharmaceuticals FAQs
-
When was Novilla Pharmaceuticals founded?
Novilla Pharmaceuticals was founded in 2019.
-
Where is Novilla Pharmaceuticals headquartered?
Novilla Pharmaceuticals is headquartered in Arlington, VA.
-
What is the size of Novilla Pharmaceuticals?
Novilla Pharmaceuticals has 9 total employees.
-
What industry is Novilla Pharmaceuticals in?
Novilla Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Novilla Pharmaceuticals a private or public company?
Novilla Pharmaceuticals is a Private company.
-
What is the current valuation of Novilla Pharmaceuticals?
The current valuation of Novilla Pharmaceuticals is .
-
What is Novilla Pharmaceuticals’s current revenue?
The current revenue for Novilla Pharmaceuticals is .
-
How much funding has Novilla Pharmaceuticals raised over time?
Novilla Pharmaceuticals has raised $27M.
-
Who are Novilla Pharmaceuticals’s investors?
MALIAM, 3rdEyeBio, Beyond The Game Network, Ringbolt Capital, and Blindspot Ventures are 5 of 7 investors who have invested in Novilla Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
